Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - Bristol-Myers Squibb may not be as aggressive as its larger multinational competitors in playing the generics or the branded generics card, but the company best known for blockbusters like Abilify (aripiprazole) and Plavix (clopidogrel) has brought under sharp focus partnership-based research for developing innovative drugs in India